Skip to main content
ZEVRA THERAPEUTICS, INC. logo

ZEVRA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · ZVRA ISIN · US4884452065 LEI · 254900CU6T74V18Y1W18 US Manufacturing
Filings indexed 830 across all filing types
Latest filing 2021-08-24 Director's Dealing
Country US United States of America
Listing US ZVRA

About ZEVRA THERAPEUTICS, INC.

https://zevra.com/

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing therapies for patients with rare diseases. The company focuses on addressing significant unmet medical needs by combining a data-driven scientific approach with a patient-first perspective. Its portfolio includes commercial products such as MIPLYFFA®, an FDA-approved treatment for Niemann-Pick disease type C (NPC), and OLPRUVA®. Zevra Therapeutics also maintains a late-stage clinical pipeline, specializing in advancing promising medicines that face complex clinical and regulatory challenges for conditions with limited or no available treatments.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2021-08-24 English
FORM 4
Director's Dealing
2021-08-24 English
FORM 4
Director's Dealing
2021-08-24 English
FORM 4
Director's Dealing
2021-08-24 English
FORM 424B3
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated August 18, 2021, announcing the appointment of Tamara A. Seymour to the company's board of directors and as chair of the audit committee. It includes detailed biographical information about the new director, her compensation, and related governance details. The document is not a full annual or quarterly report, nor is it an earnings release or a proxy statement. It specifically relates to a change in the company's board of directors, which fits the category of Board/Management Information (MANG). The document length is substantial (15,000 characters), and it contains detailed substantive information about the management change, not just a brief announcement or press release. Therefore, the appropriate classification is MANG with high confidence.
2021-08-20 English
FORM 3
Director's Dealing
2021-08-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.